United States - English - NLM (National Library of Medicine)

physicians total care, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril hydrochloride 10 mg - quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration ). in using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that quinapril does not have a similar risk (see warnings: neutropenia/agranulocytosis ). angioedema in black patients: black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials, ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride and hydrochlorothiazide tablets are contra

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: head and neck angioedema). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angi

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 g - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.85 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; magnesium stearate; titanium dioxide; purified talc; macrogol 6000; hyprolose; isopropyl alcohol; acetone; basic butylated methacrylate copolymer - treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril in renovascular hypertension. congestive heart failure. adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 5.425 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; magnesium stearate; titanium dioxide; purified talc; macrogol 6000; iron oxide yellow; hyprolose; isopropyl alcohol; acetone; basic butylated methacrylate copolymer - treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril in renovascular hypertension. congestive heart failure. adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

United States - English - NLM (National Library of Medicine)

apotex corp - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - hypertension quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril hydrochloride and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - hypertension: quinapril hcl and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril hcl and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - enalapril maleate - tablet - enalapril

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - enalapril maleate - tablet - enalapril